Type 2 diabetes

Some patients achieve significant improvement in blood glucose control through sustained weight management and lifestyle change, and a minority reach remission by standard clinical definitions (HbA1c below 6.5% for at least 3 months off medication) — the DiRECT trial found roughly two-thirds of participants achieved remission within 10 years of diagnosis after substantial weight loss, but this varies by individual and isn't guaranteed. Discuss realistic goals with your care team.

Not necessarily. Many people manage type 2 diabetes with oral medication and lifestyle measures for years; insulin becomes appropriate for some patients as the condition progresses. See our insulin therapy page for detail.

Studies place the "take-off" age for rising diabetes risk in India at 25–34, notably younger than in Western populations, with Indian patients often developing diabetes at a lower BMI and showing disproportionate insulin resistance relative to body weight — reasons why age and BMI alone shouldn't be used to dismiss risk.

With blood tests against standard thresholds: a fasting glucose of 126 mg/dL or higher, HbA1c of 6.5% or higher, a 2-hour oral glucose tolerance test result of 200 mg/dL or higher, or a random glucose of 200 mg/dL or higher with classic symptoms.

Blood glucose levels higher than normal but not yet in the diabetes range — a stage where lifestyle changes, and sometimes medication, can meaningfully reduce the risk of progressing to type 2 diabetes.

No — GLP-1 and dual-action medicines are preferred as part of first-line choice specifically for appropriately selected patients with overweight or obesity, but the decision is individualized to your overall risk profile, other conditions, and preferences, not applied as a blanket rule.

Yes — metformin remains a foundational, widely used medicine for many patients with type 2 diabetes, often used alongside or before other options depending on your individual treatment plan.

Nerve health (diabetic peripheral neuropathy), kidney function, circulation (peripheral vascular disease), and foot risk are all part of standard, ongoing screening — see the related pages on this site for how each is specifically assessed.

Typically every 3 to 6 months, depending on how stable your glucose control is and whether your treatment has recently changed — your care team will advise a schedule suited to you.

A family history of type 2 diabetes is a recognized risk factor, though it isn't the only one — insulin resistance, weight, activity level, and age all contribute alongside genetics.

For some patients, particularly earlier in the disease course, yes — for others, medication is needed alongside lifestyle measures to reach target glucose control. This is individualized and reassessed over time rather than assumed either way from the outset.

Remission means blood glucose has returned to non-diabetic levels without medication, but it requires ongoing monitoring since it can be lost — it isn't the same as a permanent cure, and the underlying tendency toward diabetes generally remains.

This depends on your specific treatment — it's generally more important if you're on insulin or medicines that can cause low blood glucose, and less central for some patients managed with lifestyle measures or certain oral medicines alone. Your care team will advise what's useful for you.

For appropriately selected patients with obesity, yes — metabolic/bariatric surgery is an established option with its own specific criteria. See our obesity/weight management page for detail on the staged treatment approach, including surgery.

Type 2 diabetes frequently develops gradually with no symptoms at all in its early stages, which is exactly why screening (rather than waiting for symptoms) matters, particularly given how early risk can begin in Indian populations.